39 studies found for:    Open Studies | "beta-Thalassemia"
Show Display Options
Rank Status Study
21 Recruiting HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity
Conditions: Sickle Cell Disease;   Beta Thalassemia-Major
Interventions: Drug: alemtuzumab (Campath IH);   Drug: Fludarabine;   Drug: Melphalan;   Drug: Cyclosporine;   Drug: Mycophenolate mofetil;   Drug: Tacrolimus;   Biological: Hematopoietic Stem Cell Transplantation
22 Recruiting B-Thalasaemia Trait and Its Possible Cardioprotective Role
Conditions: Beta-Thalassemia Trait;   Coronary Artery Disease
Intervention:
23 Recruiting Decision Aid for Therapeutic Options In Sickle Cell Disease
Conditions: Sickle Cell Disease;   Sickle Cell Anemia;   Hemoglobin SS;   Hemoglobin SC;   Hemoglobin Beta Thalassemia
Interventions: Other: Decision Aid;   Other: Standard Practice
24 Recruiting Detection of β Thalassemia Carriers by Red Cell Parameters Obtained From the H2 Automatic Counter
Conditions: Thalassemia;   Iron Deficiency
Intervention: Procedure: Observation of results from laboratory tests
25 Unknown  A Case Control Study to Evaluate the Cognitive and Brain Function of β-thalassemia Patients.
Conditions: Thalassemia;   Brain Function (Measured by ERP Level)
Intervention:
26 Recruiting Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia
Conditions: Peripheral Blood Stem Cell Transplantation;   Anemia, Sickle Cell;   Graft-Versus-Host Disease;   Sirolimus (Rapamune );   Alemtuzumab (Campath )
Interventions: Procedure: PBMC Transplant;   Drug: Alemtuzumab (Campath  );   Drug: Sirolimus (Rapamune  );   Drug: Cyclophosphamide (Cytoxan  );   Procedure: Low Dose Irradiation
27 Not yet recruiting Role of Vitamin C to Augment Iron Chelation With DFP or DFX
Conditions: Vitamin c;   Thalassemia Major;   Iron Chelation
Interventions: Drug: Vitamin C, Defriprone, deferisarox;   Drug: deferiprone , deferesarox
28 Unknown  Therapeutic Effect and Safety of Combined Hydroxyurea With Recombinant Human Erythropoietin.
Condition: Thalassemia Intermedia
Interventions: Drug: Hydroxyurea ,Epiao;   Drug: hydroxyurea, blood transfusion
29 Recruiting Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.
Condition: Thalassemia Major
Intervention: Drug: INC424 (ruxolitinib)
30 Unknown  The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study
Condition: Thalassemia Major
Interventions: Drug: Vitamin D3;   Drug: Placebo
31 Recruiting High-Tc Susceptometer to Monitor Transfusional Iron Overload
Conditions: Transfusional Iron Overload;   Thalassemia Major;   Sickle Cell Disease;   Myelodysplastic Syndromes;   Aplastic Anemia
Intervention: Device: Hepatic biomagnetic susceptibility measurement
32 Recruiting Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia
Condition: Thalassemia Major With Severe Transfusional Iron Overload
Intervention: Drug: Deferasirox and deferiprone
33 Unknown  GDF 15 in Sickle Cell Disease and Hereditary Spherocytosis
Conditions: Patients With Thalassemia Intermedia,;   Congenital Dyserythropoietic Anemia Type I
Intervention:
34 Recruiting Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure
Conditions: Sickle Cell Disease;   Thalassemia;   Stem Cell Transplantation;   Graft vs Host Disease
Interventions: Drug: Alemtuzumab;   Drug: Sirolimus;   Drug: Cyclophosphamide;   Drug: Pentostatin;   Drug: Radiotherapy
35 Unknown  Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies
Condition: Hemoglobinopathies
Intervention: Drug: PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
36 Not yet recruiting Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients
Condition: Chronic Iron Overload
Interventions: Drug: Deferiprone;   Drug: Deferasirox
37 Recruiting Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
Condition: Sickle Cell Disease
Intervention: Drug: panobinostat
38 Recruiting CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
Conditions: Chronic Myeloid Leukemia (CML);   Acute Myelogenous Leukemia (AML);;   Myelodysplastic Syndrome (MDS);;   Juvenile Myelomonocytic Leukemia (JMML);;   Acute Lymphoblastic Leukemia (ALL);;   Lymphoma (Hodgkin's and Non-Hodgkin's)
Interventions: Device: CliniMACS CD34+ Reagent System;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Alemtuzumab;   Drug: Tacrolimus;   Drug: Melphalan;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Methylprednisolone
39 Recruiting Reduced Intensity Conditioning in Patients Aged ≤35 With Non-Malignant Disorders Undergoing UCBT, BMT, or PBSCT
Conditions: Primary Immunodeficiency Syndromes;   Congenital Bone Marrow Failure Syndromes;   Inherited Metabolic Disorders (IMD);   Hereditary Anemias;   Patients With Sickle Disease Presenting Specific Symptoms
Interventions: Drug: Hydroxyurea;   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Thiotepa

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-39) Next Page   
Indicates status has not been verified in more than two years